Psoriatic Arthritis Treatment Market By Treatment Type (Biologic Treatments, Disease Modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)), By Route of Administration (Injectable, Oral), By End-User (Hospitals, Clinics, Home Care Settings), By Distribution Channel (Direct Sales, Retail Pharmacies, Online Pharmacies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Psoriatic Arthritis Treatment Market was valued at USD 9.7 billion in 2024-e and will surpass USD 19.4 billion by 2030; growing at a CAGR of 12.2% during 2025 - 2030.

The psoriatic arthritis (PsA) treatment market is expanding as the prevalence of psoriatic arthritis rises globally. Psoriatic arthritis is a chronic inflammatory disease that affects the joints and is commonly associated with psoriasis, a skin condition. The disease causes pain, swelling, and stiffness in the joints, which can significantly impact a patient's mobility and quality of life. PsA is a progressive condition that can lead to joint damage if not effectively treated, making it crucial for patients to access timely and effective therapies. As awareness of PsA grows and diagnostic methods improve, more patients are seeking treatment, which is driving the demand for advanced therapies in the market.

Treatment options for psoriatic arthritis have evolved significantly in recent years. Biologic treatments, disease-modifying antirheumatic drugs (DMARDs), and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage the disease. Among these, biologic treatments have emerged as the most promising option, especially for patients with moderate to severe PsA. The market is benefiting from continuous advancements in drug development, with the introduction of more targeted biologic therapies that provide better efficacy and fewer side effects compared to traditional therapies. As research into the pathophysiology of psoriatic arthritis progresses, more effective treatments are expected to become available, further driving market growth.

Biologic Treatments are Largest Due to Effectiveness and Targeted Action

Biologic treatments dominate the psoriatic arthritis treatment market due to their effectiveness in controlling symptoms and preventing joint damage in patients with moderate to severe psoriatic arthritis. Biologic agents, such as TNF inhibitors (e.g., infliximab, adalimumab), IL-17 inhibitors (e.g., secukinumab), and IL-12/23 inhibitors (e.g., ustekinumab), work by targeting specific components of the immune system that contribute to the inflammatory process underlying PsA. These treatments help to reduce inflammation, prevent further joint damage, and improve overall physical function, making them the go-to therapy for patients who do not respond well to traditional DMARDs or NSAIDs.

The widespread adoption of biologics is driven by their proven ability to provide long-term relief and improve quality of life for patients. Biologics are particularly beneficial for individuals with severe psoriatic arthritis who experience significant joint pain and mobility issues. Additionally, the ability of biologics to target the immune system more precisely, resulting in fewer side effects compared to conventional treatments, has contributed to their popularity. The growth of biologic treatments in the psoriatic arthritis market is expected to continue as new biologic therapies enter the market, offering even more personalized and effective treatment options for patients.

Disease Modifying Antirheumatic Drugs (DMARDs) Are Fastest Growing Due to Comprehensive Disease Management

Disease-modifying antirheumatic drugs (DMARDs) are the fastest-growing treatment type in the psoriatic arthritis market, due to their ability to address the underlying disease processes and prevent long-term joint damage. Traditional DMARDs, such as methotrexate and sulfasalazine, are used as first-line treatments for patients with mild to moderate psoriatic arthritis. These drugs work by suppressing the immune system to reduce inflammation and prevent joint destruction. Although DMARDs have been used for decades, their ability to slow the progression of psoriatic arthritis and improve joint function has ensured their continued importance in disease management.

The growth of DMARDs is particularly notable in the early stages of PsA treatment, as they are often prescribed before biologics are considered, particularly for patients with less severe forms of the disease. Additionally, there is growing interest in the use of newer biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) that offer a more tailored approach to treatment. These newer DMARDs are expected to drive the segment’s growth as they provide more precise control over the disease while minimizing side effects. As more targeted therapies enter the market, DMARDs will continue to play a critical role in the comprehensive management of psoriatic arthritis.

Injectable Route of Administration is Largest Due to Efficacy and Convenience for Biologics

Injectable treatments represent the largest route of administration in the psoriatic arthritis treatment market, driven by the widespread use of biologic therapies. Biologic agents, which are often administered by injection (subcutaneous or intravenous), provide targeted relief for moderate to severe psoriatic arthritis. This route of administration ensures that the biologic drug is delivered directly into the bloodstream, enabling it to reach the immune system and target the underlying inflammation effectively. While injectable biologics typically require periodic administration (ranging from weekly to monthly), their ability to control symptoms and prevent disease progression makes them the preferred option for patients with more severe forms of PsA.

The popularity of injectable biologics is also driven by the fact that they offer long-lasting effects, allowing patients to experience significant symptom relief for extended periods between doses. Although some patients may prefer oral treatments due to their ease of use, the superior efficacy of injectable biologics, especially in severe cases of PsA, has cemented their dominance in the market. Additionally, the growing availability of self-administered injectable biologics, which patients can inject at home, adds to the convenience and appeal of this treatment option.

Hospitals are Largest End-User Due to Complex and Severe Cases

Hospitals are the largest end-users in the psoriatic arthritis treatment market, particularly for patients with complex or severe cases of PsA that require specialized care. Psoriatic arthritis can lead to joint deformities and significant disability if not managed effectively, making it critical for patients to receive comprehensive care from experienced rheumatologists and other specialists. Hospitals provide the infrastructure, expertise, and advanced diagnostic tools needed to manage severe forms of PsA, including the administration of biologic therapies and other advanced treatments.

In addition to biologics, hospitals are equipped to provide a full range of supportive care, such as physical therapy, joint injections, and other interventions designed to improve joint function and prevent long-term damage. Hospital settings also offer a higher level of monitoring for patients receiving biologic treatments, ensuring that any side effects or complications are promptly addressed. As PsA treatment becomes more complex and specialized, hospitals will continue to play a central role in managing the disease and delivering advanced therapies to patients.

Retail Pharmacies are Largest Distribution Channel Due to Accessibility and Convenience

Retail pharmacies are the largest distribution channel for psoriatic arthritis treatments, particularly for oral medications and non-prescription NSAIDs. Over-the-counter products like pain relievers, topical corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly sold through retail pharmacies, providing patients with convenient access to essential treatments for managing mild to moderate psoriatic arthritis symptoms. Additionally, oral DMARDs and some NSAIDs are also available through retail pharmacies, offering an accessible and cost-effective way for patients to manage their disease.

The convenience of retail pharmacies, including both brick-and-mortar stores and online platforms, makes them an important distribution channel for psoriatic arthritis treatments. Online pharmacies are gaining in popularity, providing patients with the ability to order medications from home, which is especially important for those with mobility issues or those who live in rural areas. With the continued growth of e-commerce and digital healthcare services, retail and online pharmacies are expected to remain a dominant channel in the distribution of psoriatic arthritis treatments.

North America Region is Largest Due to Advanced Healthcare Systems and Awareness

North America is the largest region in the psoriatic arthritis treatment market, driven by advanced healthcare systems, high levels of awareness, and widespread access to innovative therapies. The United States and Canada have well-established healthcare infrastructures that provide psoriatic arthritis patients with access to a wide range of treatment options, including biologics, oral medications, and DMARDs. High awareness of PsA among healthcare providers and patients has led to earlier diagnosis and more effective management of the condition, contributing to the growth of the market in the region.

In addition, North America benefits from a robust pipeline of new treatments and ongoing research into the pathophysiology of psoriatic arthritis, ensuring that patients have access to the latest therapeutic options. The region also has a high adoption rate of biologics, which are often the first-line treatment for moderate to severe PsA. As a result, North America is expected to continue to lead the psoriatic arthritis treatment market in terms of both market size and growth potential.

Leading Companies and Competitive Landscape

The psoriatic arthritis treatment market is highly competitive, with several major pharmaceutical companies at the forefront of developing innovative therapies. Key players include AbbVie, Amgen, Janssen Biotech, and Novartis, which dominate the biologics market with their TNF inhibitors, IL-17 inhibitors, and other advanced therapies. These companies invest heavily in clinical trials and research to expand their portfolios and improve the efficacy of their treatments.

In addition to large pharmaceutical companies, smaller biotech firms are making significant strides in developing targeted therapies for psoriatic arthritis. The competitive landscape is characterized by innovation, with companies focusing on improving patient outcomes through personalized treatment approaches. Partnerships, mergers, and acquisitions are common in this sector as companies seek to strengthen their market position and expand their product offerings. As the market continues to evolve, competition will remain fierce, with a strong emphasis on developing effective, long-lasting treatments for psoriatic arthritis.

Recent Developments:

• In December 2024, AbbVie Inc. launched a new TNF inhibitor for psoriatic arthritis, expanding its portfolio.
• In November 2024, Amgen Inc. reported positive trial results for a new IL-17 inhibitor designed to treat psoriatic arthritis.
• In October 2024, Pfizer received approval for an oral JAK inhibitor for psoriatic arthritis treatment.
• In September 2024, Johnson & Johnson expanded its biologic offerings with a new treatment for psoriatic arthritis.
• In August 2024, Novartis International AG announced an update on its IL-12/23 inhibitor, showing strong efficacy in clinical trials for psoriatic arthritis.
   

List of Leading Companies:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis International AG
• Pfizer Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb
• UCB S.A.
• Merck & Co., Inc.
• Sanofi S.A.
• Celgene Corporation
• Horizon Therapeutics
• Astellas Pharma
• Regeneron Pharmaceuticals
• Gilead Sciences, Inc.

Report Scope: